Lunsumio(mosunetuzumab-axgb)

【 indications of Lunsumio(mosunetuzumab-axgb) 】
It is used to treat adult patients with recurrent or refractory (R/R) follicular lymphoma (FL) after two or more systematic treatment series.

It is not clear whether Lunsumio children are safe and effective.

[Lunsumio(mosunetuzumab-axgb) box warning]
Cytokine release syndrome (CRS), including severe or life-threatening reactions, can occur in patients receiving Lunsumio. Lunsumio incremental dose regimen was started to reduce the risk of CRS. Pause Lunsumio until CRS is resolved or permanently stopped according to severity.

[Lunsumio(mosunetuzumab-axgb) is used in a specific population]
breast-feed
There is no information about the presence of mosunetuzumab-axgb in breast milk, its effects on breast-fed infants or milk production. Because human IgG exists in breast milk, and the absorption of mosunetuzumab-axgb may lead to B cell exhaustion, it is suggested that women should not breastfeed for 3 months after the last dose of Lunsumio treatment.

[Adverse reaction of Lunsumio(mosunetuzumab-axgb)]
The most common adverse reactions (≥20%) were CRS (39%), fatigue (36%), rash (34%), fever (24%) and headache (21%).